Infections, Papillomavirus
Conditions
Keywords
HPV, Human papillomavirus (HPV) vaccine, Human Immunodeficiency Virus (HIV), Cervical cancer, Papillomavirus
Brief summary
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 in HIV infected adult females living in the Republic of South Africa. The study is double blinded, randomized for HIV positive subjects and open for HIV negative subjects. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
BIOLOGICALCervarix
Intramuscular injection, 3 doses
BIOLOGICALPlacebo Control
Intramuscular injection, 3 doses
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes that they can and will comply with the requirements of the protocol * A female between, and including, 18 and 25 years of age at the time of the first vaccination. * Written, signed or thumb-printed informed consent obtained from the subject prior to enrolment. * Subjects willing to undergo HIV Voluntary Counseling and Testing (VCT) and willing to be informed of their HIV status. * Subjects willing to provide place of residence and be visited at home. * HIV seropositive subjects: 1. Subjects must be HIV seropositive according to WHO case definition 2. Subjects with WHO Clinical Stage 1 HIV-associated disease 3. Subjects currently on antiretroviral therapy (ART) must be compliant to ART and have undetectable viral load * HIV seronegative subjects: Subjects confirmed as HIV seronegative at the screening visit are eligible to participate in the HIV-/HPV group of the study. * Non-virgin subjects must have a normal colposcopy at the screening visit. * Non-virgin subjects must have a normal cervical cytology (Pap smear) or no greater than atypical squamous cells of undetermined significance (ASC-US) at the screening visit. * All subjects must have a negative urine pregnancy test at the screening visit and at visit 1 (Day 0). * Subjects must be of non-childbearing potential or, if of childbearing potential, must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series. * Subjects must have had no more than 6 life-time sexual partners prior to enrolment. * Subjects must have one single intact cervix
Exclusion criteria
* Active tuberculosis (TB) * Current TB prophylaxis or therapy. * Anemia at the screening visit. * increased creatinine at the screening visit. * Increased hepatic enzym (ALT) at the screening visit * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine/control, or planned use during the entire study period (up to Month 12). * Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose. * Administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine/control. Enrolment will be postponed until the subject is outside the specified window. * Planned administration of a vaccine not foreseen by the study protocol within 30 days before or 30 days after (i.e., Days 0-29) any dose of study vaccine. * Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period (Month 0 to Month 12). * previous administration of components of the investigational vaccine * Cancer or autoimmune disease under treatment. * Hypersensitivity to latex. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine/control. * Acute disease at the time of enrolment. * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory testing performed at the screening visit. * History of any neurological disorders or seizures. * Pregnant or breastfeeding female. * A subject planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose. * Concurrently participating in another clinical study, at any time during the study period (up to Month 12), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). * Any medically diagnosed or suspected immunodeficient condition (other than HIV for HIV seropositive subjects), based on medical history, physical examination and/or laboratory tests results. * Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine/control or planned administration during the study period. Enrolment will be postponed until the subject is outside the specified window. * Administration of trimethoprim/sulphamethoxazole within 7 days before the first dose of study vaccine/control, or planned administration of trimethoprim/sulphamethoxazole within 7 days after the first dose of study vaccine/control. * Current drugs or alcohol abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Within 7 days after each dose and across doses | Solicited local symptoms assessed were pain and swelling. Any = occurrence of any solicited local regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 swelling = swelling spreading beyond 50 millimeters (mm) of injection site. Solicited local symptoms were assessed as related to the study vaccination. |
| Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Within 7 days after each dose and across doses | Solicited general symptoms assessed were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal, headache, myalgia, rash and urticaria. Any = occurrence of any solicited general symptom regardless of their intensity grade or relationship. Grade 3 Symptom = symptom that prevented normal activity. Grade 3 Urticaria = Urticaria distributed on at least 4 body areas. Related = symptom assessed by the investigator as causally related to the vaccination. |
| Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Within 30 days after any vaccination | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. |
| Number of Subjects With Medically Significant Conditions (MSCs) From Day 0 up to Month 7 | From Day 0 up to Month 7 | Medically significant conditions (MSCs) were collected regardless of causal relationship to vaccination and intensity. Medically significant conditions were defined as adverse events (AEs) prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or serious adverse events (SAEs) that were not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury. |
| Number of Subjects Reporting Serious Adverse Events (SAEs) From Day 0 up to Month 7 | From Day 0 up to Month 7 | SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject. |
| Number of Subjects With Pregnancies and Outcomes of Reported Pregnancies From Day 0 up to Month 7 | From Day 0 up to Month 7 | The subjects with confirmed pregnancies were followed up to determine the outcomes of the reported pregnancies. The outcome of the reported pregnancy was a live infant with no apparent congenital anomaly. |
| Number of Subjects Reporting SAEs From Day 0 up to Month 12 | From Day 0 up to Month 12 | SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject. |
| Number of Subjects With MSCs From Day 0 up to Month 12 | From Day 0 up to Month 12 | MSCs were collected regardless of causal relationship to vaccination and intensity. Medically significant conditions were defined as adverse events (AEs) prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or serious adverse events (SAEs) that were not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury. |
| Number of Subjects With Pregnancies and Outcomes of Reported Pregnancies From Day 0 up to Month 12 | From Day 0 up to Month 12 | The subjects with confirmed pregnancies were followed up to determine the outcomes of the reported pregnancies. The outcome of the reported pregnancy was a live infant with no apparent congenital anomaly. |
| Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | At Day 7 and at Months 1, 2, 4, 6 and 7 | Haematological laboratory parameters assessed were red blood cells (RBC) and platelets (PLA). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated). |
| Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | At Day 7 and Months 1, 2, 4, 6 and 7 | Haematological laboratory parameters assessed were white blood cells (WBC) and neutrophils (NEU). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated). |
| Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | At Day 7 and at Months 1, 2, 4, 6 and 7 | Haematological laboratory parameters assessed were lymphocytes (LYM) and monocytes (MON). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated). |
| Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | At Day 7 and Months 1, 2, 4, 6 and 7 | Haematological laboratory parameters assessed were haemoglobin (Hgb) and haematocrit (Hct). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated). |
| Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | At Day 7 and at Months 1, 2, 4, 6 and 7 | Haematological and biochemical laboratory parameters assessed were eosinophils (EOS), basophils (BAS) and creatinine (CREA). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated). |
| Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | At Day 7 and Months 1, 2, 4, 6 and 7 | Biochemical laboratory parameter assessed was alanine aminotransferase (ALAT). By pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated). |
| Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | At Month 10 and Month 12 | Haematological laboratory parameters assessed were neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated). |
| Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | At Month 10 and Month 12 | Haematological and biochemical laboratory parameters assessed were alanine aminotransferase (ALAT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocrit (Hct), haemoglobin (Hgb), lymphocytes (LYM) and monocytes (MON). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated). |
| Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | At pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | The number of CD4+ cells per cubic millimeter (mm\^3) in all HIV+ subjects at pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 is reported. |
| Number of CD4+ Cells Per Cubic Millimeter in All HIV+ Subjects at Month 10 and Month 12 | At Month 10 and Month 12 | The number of CD4+ cells per cubic millimeter (mm\^3) in all HIV+ subjects at Month 10 and Month 12 is reported. |
| HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | At pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | The viral load was calculated by estimating the amount of virus in blood samples and it was given in number of Ribonucleic acid copies per milliliter (in log10) \[RNA copies/mL (in log10)\]. |
| HIV Viral Load in All HIV+ Subjects at Month 10 and Month 12 | At Month 10 and Month 12 | The viral load was calculated by estimating the amount of virus in blood samples and was given in number of RNA copies/mL (in log 10). |
| Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | At Months 1, 2, 4, 6 and 7 | CD4+ cell count categories, at baseline, assessed were (i) below (\<) 200 CD4+ cells per cubic millimeter (mm\^3), (ii) between 200 and 500 CD4+ cells/mm\^3 and (iii) above 500 CD4+ cells/mm\^3. WHO classification of HIV-associated clinical disease: 1 = Asymptomatic HIV-associated symptoms = WHO clinical stage 1; 2 = Mild HIV-associated symptoms = WHO clinical stage 2; 3 = Advanced HIV-associated symptoms = WHO clinical stage 3; 4 = Severe HIV-associated symptoms = WHO clinical stage 4. |
| Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | At Month 10 and Month 12 | CD4+ cell count categories, at baseline, assessed were: (i) below (\<) 200 CD4+ cells per cubic millimeter (mm\^3), (ii) between 200 and 500 CD4+ cells/mm\^3 and (iii) above (\>) 500 CD4+ cells/mm\^3. WHO classification of HIV-associated clinical disease: 1 = Asymptomatic HIV-associated symptoms = WHO clinical stage 1; 2 = Mild HIV-associated symptoms = WHO clinical stage 2; 3 = Advanced HIV-associated symptoms = WHO clinical stage 3; 4 = Severe HIV-associated symptoms = WHO clinical stage 4. |
| Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | At pre-vaccination (Day 0) and Months 2 and 7 | Seroconversion is defined as the appearance of anti-HPV-16 and/or anti-HPV-18 antibodies (anti-HPV-16 titers ≥ 8 EL.U/mL and anti-HPV-18 titers ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject whose antibody titers are below the cut-off value. Due to the high proportion of initially seropositive subjects in the study population, seroconversion rates were considered for all subjects in the According-to-Protocol (ATP) cohort for immunogenicity regardless of baseline serostatus. |
| Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Month 12 | At Month 12 | Seroconversion is defined as the appearance of anti-HPV-16 and/or anti-HPV-18 antibodies (anti-HPV-16 titers ≥ 8 ELISA units per milliliter (EL.U/mL) and anti-HPV-18 titers ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject whose antibody titers are below the cut-off value. Due to the high proportion of initially seropositive subjects in the study population, seroconversion rates were considered for all subjects in the ATP cohort for immunogenicity regardless of baseline serostatus. |
| CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | At Month 7 | The CMI response is expressed by the number of subjects with B-cell response to VLP-16 and VLP-18 above (\>) 0 as measured by Flow cytometry. |
| CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | At Month 12 | The CMI response is expressed by the number of subjects with B-cell response to VLP-16 and VLP-18 above (\>) 0 as measured by Flow cytometry. |
| Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | At pre-vaccination (Day 0) and Months 2 and 7 | Concentrations are expressed as geometric mean antibody concentrations (GMCs) and are given in EL.U/mL. The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off values of the assay are 8 EL.U/mL for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18. |
| Concentrations for HPV-16 and HPV-18 Antibodies at Month 12 | At Month 12 | Concentrations are expressed as geometric mean antibody concentrations (GMCs) and are given in EL.U/mL. The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off values of the assay are 8 EL.U/mL for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18. |
| Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | At pre-vaccination (Day 0) | The CMI response is expressed by the number of subjects with B-cell response to VLP-16 and VLP-18 above (\>) 0 as measured by Flow cytometry. |
| CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | At Month 2 | The CMI response is expressed by the number of subjects with B-cell response to VLP-16 and VLP-18 above (\>) 0 as measured by Flow cytometry. |
| CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | At pre-vaccination (Day 0) and at Months 2, 7 and 12 | The CMI response is the measure of the cytokines production \[i.e. Cluster of Differentiation 40 Ligand (CD40L), Interferon gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α)\] by HPV-antigen specific T lymphocytes and measured by Intracellular Cytokine Staining (ICS) assay. The results were expressed as a frequency of positive CD4 or CD8 T-cell producing at least 1 cytokine within the CD4 or CD8 T-cell sub-population. All doubles = T cell expressing at least 2 cytokines. |
Countries
South Africa
Participant flow
Recruitment details
HIV+ subjects were randomised to receive either Cervarix or Aluminium Hydroxide vaccines; HIV- subjects were not randomised and all received Cervarix vaccine.
Pre-assignment details
Enrollment was staggered as follows: 1) Enrollment of Human immunodeficiency virus positive (HIV+) subjects with cluster of differentiation 4 (CD4+) cell count \>200 cells per cubic millimeter (cells/mm\^3) and HIV negative (HIV-) subjects (up to 30 subjects) for blinded safety evaluation; 2) Enrollment of remaining HIV+/HIV- subjects.
Participants by arm
| Arm | Count |
|---|---|
| HIV+/Cervarix Group Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm, according to a 0, 1, 6-month schedule. | 61 |
| HIV+/Aluminium Hydroxide Group Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of control Aluminium Hydroxide \[Al(OH)3\], administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule. | 59 |
| HIV-/Cervarix Group Human immunodeficiency virus negative (HIV-) subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule. | 30 |
| Total | 150 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 3 | 2 | 1 |
| Overall Study | Migrated/moved from study area | 3 | 2 | 4 |
| Overall Study | Withdrawal by Subject | 1 | 3 | 1 |
Baseline characteristics
| Characteristic | HIV+/Cervarix Group | HIV+/Aluminium Hydroxide Group | HIV-/Cervarix Group | Total |
|---|---|---|---|---|
| Age, Continuous | 21.6 Years STANDARD_DEVIATION 2.21 | 22.7 Years STANDARD_DEVIATION 1.7 | 21.3 Years STANDARD_DEVIATION 1.65 | 21.9 Years STANDARD_DEVIATION 1.85 |
| Race/Ethnicity, Customized African heritage/African American | 61 Participants | 59 Participants | 30 Participants | 150 Participants |
| Sex: Female, Male Female | 61 Participants | 59 Participants | 30 Participants | 150 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 61 | 0 / 59 | 0 / 30 |
| other Total, other adverse events | 61 / 61 | 55 / 59 | 29 / 30 |
| serious Total, serious adverse events | 3 / 61 | 2 / 59 | 1 / 30 |
Outcome results
Primary
Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0
The CMI response is expressed by the number of subjects with B-cell response to VLP-16 and VLP-18 above (\>) 0 as measured by Flow cytometry.
Time frame: At pre-vaccination (Day 0)
Population: The analysis was performed on the ATP cohort for immunogenicity (Month 12), which included all evaluable subjects up to Month 12 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, >0 | 14 Participants |
| HIV+/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, =0 | 8 Participants |
| HIV+/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, Missing | 20 Participants |
| HIV+/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, =0 | 5 Participants |
| HIV+/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, >0 | 16 Participants |
| HIV+/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, Missing | 21 Participants |
| HIV+/Aluminium Hydroxide Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, Missing | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, >0 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, =0 | 13 Participants |
| HIV+/Aluminium Hydroxide Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, =0 | 15 Participants |
| HIV+/Aluminium Hydroxide Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, >0 | 13 Participants |
| HIV+/Aluminium Hydroxide Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, Missing | 11 Participants |
| HIV-/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, >0 | 6 Participants |
| HIV-/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, Missing | 6 Participants |
| HIV-/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, Missing | 6 Participants |
| HIV-/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, =0 | 6 Participants |
| HIV-/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-16, =0 | 10 Participants |
| HIV-/Cervarix Group | Cell Mediated Immune (CMI) Response (B-cell Responses) Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Day 0 | VLP-18, >0 | 10 Participants |
Primary
CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12
The CMI response is expressed by the number of subjects with B-cell response to VLP-16 and VLP-18 above (\>) 0 as measured by Flow cytometry.
Time frame: At Month 12
Population: The analysis was performed on the ATP cohort for immunogenicity (Month 12), which included all evaluable subjects up to Month 12 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, =0 | 8 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, >0 | 21 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, Missing | 13 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, =0 | 13 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, >0 | 13 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, Missing | 16 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, Missing | 13 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, =0 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, =0 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, >0 | 14 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, >0 | 16 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, Missing | 12 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, >0 | 18 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, Missing | 2 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, Missing | 4 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, =0 | 3 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-16, =0 | 2 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 12 | VLP-18, >0 | 15 Participants |
Primary
CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2
The CMI response is expressed by the number of subjects with B-cell response to VLP-16 and VLP-18 above (\>) 0 as measured by Flow cytometry.
Time frame: At Month 2
Population: The analysis was performed on the ATP cohort for immunogenicity (Month 12), which included all evaluable subjects up to Month 12 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, =0 | 8 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, >0 | 20 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, Missing | 14 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, =0 | 11 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, >0 | 17 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, Missing | 14 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, Missing | 20 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, =0 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, =0 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, >0 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, >0 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, Missing | 21 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, >0 | 11 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, Missing | 9 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, Missing | 9 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, =0 | 2 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-16, =0 | 2 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 2 | VLP-18, >0 | 11 Participants |
Primary
CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7
The CMI response is expressed by the number of subjects with B-cell response to VLP-16 and VLP-18 above (\>) 0 as measured by Flow cytometry.
Time frame: At Month 7
Population: The analysis was performed on the ATP cohort for immunogenicity (Month 12), which included all evaluable subjects up to Month 12 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, =0 | 2 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, >0 | 24 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, Missing | 16 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, =0 | 0 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, >0 | 25 Participants |
| HIV+/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, Missing | 17 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, Missing | 11 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, =0 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, =0 | 15 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, >0 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, >0 | 16 Participants |
| HIV+/Aluminium Hydroxide Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, Missing | 12 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, >0 | 21 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, Missing | 0 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, Missing | 2 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, =0 | 1 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-16, =0 | 1 Participants |
| HIV-/Cervarix Group | CMI B-cell Responses Related to HPV 16/18 Virus-like Particles (VLPs) Measured by Flow Cytometry at Month 7 | VLP-18, >0 | 19 Participants |
Primary
CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS)
The CMI response is the measure of the cytokines production \[i.e. Cluster of Differentiation 40 Ligand (CD40L), Interferon gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α)\] by HPV-antigen specific T lymphocytes and measured by Intracellular Cytokine Staining (ICS) assay. The results were expressed as a frequency of positive CD4 or CD8 T-cell producing at least 1 cytokine within the CD4 or CD8 T-cell sub-population. All doubles = T cell expressing at least 2 cytokines.
Time frame: At pre-vaccination (Day 0) and at Months 2, 7 and 12
Population: The analysis was performed on the ATP cohort for immunogenicity (Month 12), which included all evaluable subjects up to Month 12 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-16], At Month 7 | 4329.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 12 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Day 0 | 18.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-16], At Month 12 | 2946.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 2 | 3940.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 12 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-18], At Day 0 | 132.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 12 | 3063.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 7 | 26.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-18], At Month 2 | 2527.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 2 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 7 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-18], At Month 7 | 2664.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 7 | 3400.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 2 | 28.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-18], At Month 12 | 1533.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 2 | 4082.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Day 0 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Day 0 | 148.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Day 0 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 12 | 39.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 2 | 3131.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 12 | 2569.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 7 | 40.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 7 | 4315.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Day 0 | 21.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 2 | 65.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 12 | 2662.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 12 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Day 0 | 51.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Day 0 | 150.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Day 0 | 150.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 12 | 53.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 2 | 2319.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Day 0 | 218.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 7 | 38.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 7 | 2689.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 7 | 20.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 2 | 65.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 12 | 1542.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 2 | 2467.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Day 0 | 43.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Day 0 | 256.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 2 | 24.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 7 | 2247.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 12 | 35.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Day 0 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 12 | 1484.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 2 | 2658.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 12 | 29.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-16], At Day 0 | 57.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 7 | 28.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 7 | 33.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-16], At Month 2 | 1748.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 7 | 25.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 2 | 37.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-16], At Month 7 | 1807.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 7 | 2917.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Day 0 | 39.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-16], At Month 12 | 735.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 7 | 4717.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 12 | 47.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-18], At Day 0 | 25.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 2 | 34.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 7 | 25.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-18], At Month 2 | 1045.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 12 | 1694.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 2 | 39.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-18], At Month 7 | 915.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 12 | 28.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Day 0 | 35.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-18], At Month 12 | 341.5 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Day 0 | 26.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Month 12 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-16], At Day 0 | 187.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Day 0 | 200.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Month 7 | 7.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-16], At Month 2 | 3716.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 2 | 38.0 T cells/million cells |
| HIV+/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8- CD40L [HPV-18], At Month 2 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 2 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 7 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Day 0 | 154.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 2 | 154.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 7 | 177.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 12 | 184.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Day 0 | 114.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 2 | 156.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 7 | 143.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 12 | 220.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Day 0 | 101.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 2 | 125.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 7 | 143.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 12 | 162.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Day 0 | 98.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 2 | 142.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 7 | 108.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 12 | 178.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-16], At Day 0 | 57.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-16], At Month 2 | 50.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-16], At Month 7 | 51.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-16], At Month 12 | 49.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-18], At Day 0 | 40.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-18], At Month 2 | 43.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-18], At Month 7 | 31.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-18], At Month 12 | 39.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-16], At Day 0 | 104.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-16], At Month 2 | 79.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-16], At Month 7 | 113.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-16], At Month 12 | 135.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-18], At Day 0 | 76.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-18], At Month 2 | 103.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-18], At Month 7 | 87.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-18], At Month 12 | 134.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Day 0 | 132.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 2 | 105.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 7 | 154.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 12 | 135.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Day 0 | 84.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 2 | 94.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 7 | 109.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 12 | 138.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Day 0 | 40.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 2 | 40.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 7 | 32.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 12 | 37.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Day 0 | 11.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 2 | 39.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 7 | 35.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 12 | 35.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Day 0 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 7 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 12 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Day 0 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8- CD40L [HPV-18], At Month 2 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Month 7 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Month 12 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Day 0 | 25.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 2 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 7 | 23.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 12 | 28.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Day 0 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 2 | 27.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 7 | 22.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 12 | 31.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Day 0 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 2 | 20.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 7 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 12 | 7.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Day 0 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 2 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 12 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Day 0 | 34.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 2 | 28.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 7 | 15.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 12 | 9.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Day 0 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 2 | 7.0 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 7 | 25.5 T cells/million cells |
| HIV+/Aluminium Hydroxide Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 12 | 18.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Day 0 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-16], At Month 2 | 1601.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 7 | 3121.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8- CD40L [HPV-18], At Month 2 | 38.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-16], At Day 0 | 176.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 12 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Month 7 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-18], At Month 12 | 436.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 12 | 1783.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-18], At Month 12 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-18], At Month 7 | 626.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Day 0 | 259.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Day 0 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-18], At Month 2 | 407.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Day 0 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 2 | 39.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-18], At Day 0 | 54.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 7 | 1834.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 7 | 28.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-16], At Month 12 | 592.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 2 | 28.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-16], At Month 12 | 26.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IFN-γ [HPV-16], At Month 7 | 900.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 2 | 30.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Day 0 | 9.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-16], At Month 2 | 760.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Month 2 | 1065.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 2 | 53.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IFN-γ [HPV-16], At Day 0 | 66.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 2 | 1691.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 7 | 38.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 12 | 1587.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 7 | 28.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IFN-γ [HPV-18], At Month 12 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 7 | 1524.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-18], At Day 0 | 273.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Day 0 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Month 2 | 974.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 12 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 2 | 32.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-18], At Day 0 | 222.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-16], At Month 12 | 26.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 12 | 1650.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 7 | 28.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Day 0 | 26.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 7 | 1526.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 12 | 2201.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 2 | 48.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Month 2 | 982.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-ALL DOUBLES [HPV-16], At Month 12 | 2490.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 7 | 48.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-18], At Day 0 | 229.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-16], At Month 12 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-16], At Month 12 | 45.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 12 | 2133.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 7 | 2303.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Day 0 | 31.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 7 | 2479.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Month 7 | 22.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 2 | 62.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Month 2 | 1332.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Day 0 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 7 | 44.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-TNF-α [HPV-16], At Day 0 | 185.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Month 2 | 1437.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-ALL DOUBLES [HPV-18], At Month 12 | 21.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-18], At Month 12 | 1633.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-TNF-α [HPV-18], At Day 0 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Day 0 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-18], At Month 7 | 1572.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-18], At Month 2 | 921.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 2 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-IL-2 [HPV-18], At Day 0 | 206.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 2 | 11.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 7 | 24.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-16], At Month 12 | 2366.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-IL-2 [HPV-18], At Month 7 | 17.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD8-CD40L [HPV-16], At Month 12 | 7.0 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4- IL-2 [HPV-16], At Month 7 | 2830.5 T cells/million cells |
| HIV-/Cervarix Group | CMI Response (T-cell Responses) Related to HPV-16 and HPV-18 Measured by Intracellular Cytokine Staining (ICS) | CD4-CD40L [HPV-16], At Day 0 | 208.0 T cells/million cells |
Primary
Concentrations for HPV-16 and HPV-18 Antibodies at Month 12
Concentrations are expressed as geometric mean antibody concentrations (GMCs) and are given in EL.U/mL. The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off values of the assay are 8 EL.U/mL for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18.
Time frame: At Month 12
Population: The analysis was performed on the ATP cohort for immunogenicity (Month 12), which included all evaluable subjects up to Month 12 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| HIV+/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-16, At Month 12 | 748.1 EL.U/mL |
| HIV+/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-18, At Month 12 | 343.1 EL.U/mL |
| HIV+/Aluminium Hydroxide Group | Concentrations for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-16, At Month 12 | 20.7 EL.U/mL |
| HIV+/Aluminium Hydroxide Group | Concentrations for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-18, At Month 12 | 13.0 EL.U/mL |
| HIV-/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-16, At Month 12 | 2793.6 EL.U/mL |
| HIV-/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-18, At Month 12 | 1021.3 EL.U/mL |
Primary
Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7
Concentrations are expressed as geometric mean antibody concentrations (GMCs) and are given in EL.U/mL. The antibody concentrations against HPV-16 and HPV-18 were determined by Enzyme-linked immunosorbent assay (ELISA). The cut-off values of the assay are 8 EL.U/mL for anti-HPV-16 and 7 EL.U/mL for anti-HPV-18.
Time frame: At pre-vaccination (Day 0) and Months 2 and 7
Population: The analysis was performed on the ATP cohort for immunogenicity (Month 7), which included all evaluable subjects up to Month 7 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| HIV+/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Day 0 | 13.2 EL.U/mL |
| HIV+/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 2 | 1339.3 EL.U/mL |
| HIV+/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 7 | 1952.1 EL.U/mL |
| HIV+/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Day 0 | 29.7 EL.U/mL |
| HIV+/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 2 | 2245.2 EL.U/mL |
| HIV+/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 7 | 3583.1 EL.U/mL |
| HIV+/Aluminium Hydroxide Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Day 0 | 25.7 EL.U/mL |
| HIV+/Aluminium Hydroxide Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 2 | 16.9 EL.U/mL |
| HIV+/Aluminium Hydroxide Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Day 0 | 12.5 EL.U/mL |
| HIV+/Aluminium Hydroxide Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 7 | 27.2 EL.U/mL |
| HIV+/Aluminium Hydroxide Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 7 | 14.5 EL.U/mL |
| HIV+/Aluminium Hydroxide Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 2 | 32.9 EL.U/mL |
| HIV-/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 7 | 3755.3 EL.U/mL |
| HIV-/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Day 0 | 11.1 EL.U/mL |
| HIV-/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Day 0 | 21.8 EL.U/mL |
| HIV-/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 7 | 7871.9 EL.U/mL |
| HIV-/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 2 | 2380.2 EL.U/mL |
| HIV-/Cervarix Group | Concentrations for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 2 | 6166.8 EL.U/mL |
Primary
HIV Viral Load in All HIV+ Subjects at Month 10 and Month 12
The viral load was calculated by estimating the amount of virus in blood samples and was given in number of RNA copies/mL (in log 10).
Time frame: At Month 10 and Month 12
Population: The analysis was performed on the Total Vaccinated cohort, which included all HIV+ vaccinated subjects for whom data were available at the considered time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV+/Cervarix Group | HIV Viral Load in All HIV+ Subjects at Month 10 and Month 12 | Month 10 | 4.5 RNA copies/mL (in log10) |
| HIV+/Cervarix Group | HIV Viral Load in All HIV+ Subjects at Month 10 and Month 12 | Month 12 | 4.5 RNA copies/mL (in log10) |
| HIV+/Aluminium Hydroxide Group | HIV Viral Load in All HIV+ Subjects at Month 10 and Month 12 | Month 10 | 4.5 RNA copies/mL (in log10) |
| HIV+/Aluminium Hydroxide Group | HIV Viral Load in All HIV+ Subjects at Month 10 and Month 12 | Month 12 | 4.5 RNA copies/mL (in log10) |
Primary
HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7
The viral load was calculated by estimating the amount of virus in blood samples and it was given in number of Ribonucleic acid copies per milliliter (in log10) \[RNA copies/mL (in log10)\].
Time frame: At pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all HIV+ vaccinated subjects for whom data were available at the considered time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV+/Cervarix Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Pre-vaccination (Day 0) | 4.4 RNA copies/mL (in log10) |
| HIV+/Cervarix Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 1 | 4.4 RNA copies/mL (in log10) |
| HIV+/Cervarix Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 2 | 4.4 RNA copies/mL (in log10) |
| HIV+/Cervarix Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 4 | 4.5 RNA copies/mL (in log10) |
| HIV+/Cervarix Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 6 | 4.6 RNA copies/mL (in log10) |
| HIV+/Cervarix Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 7 | 4.5 RNA copies/mL (in log10) |
| HIV+/Aluminium Hydroxide Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 6 | 4.5 RNA copies/mL (in log10) |
| HIV+/Aluminium Hydroxide Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Pre-vaccination (Day 0) | 4.4 RNA copies/mL (in log10) |
| HIV+/Aluminium Hydroxide Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 4 | 4.5 RNA copies/mL (in log10) |
| HIV+/Aluminium Hydroxide Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 1 | 4.2 RNA copies/mL (in log10) |
| HIV+/Aluminium Hydroxide Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 7 | 4.5 RNA copies/mL (in log10) |
| HIV+/Aluminium Hydroxide Group | HIV Viral Load in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 2 | 4.6 RNA copies/mL (in log10) |
Primary
Number of CD4+ Cells Per Cubic Millimeter in All HIV+ Subjects at Month 10 and Month 12
The number of CD4+ cells per cubic millimeter (mm\^3) in all HIV+ subjects at Month 10 and Month 12 is reported.
Time frame: At Month 10 and Month 12
Population: The analysis was performed on the Total Vaccinated cohort, which included all HIV+ vaccinated subjects for whom data were available at the considered time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of CD4+ Cells Per Cubic Millimeter in All HIV+ Subjects at Month 10 and Month 12 | Month 10 | 427.0 cells/mm^3 |
| HIV+/Cervarix Group | Number of CD4+ Cells Per Cubic Millimeter in All HIV+ Subjects at Month 10 and Month 12 | Month 12 | 450.5 cells/mm^3 |
| HIV+/Aluminium Hydroxide Group | Number of CD4+ Cells Per Cubic Millimeter in All HIV+ Subjects at Month 10 and Month 12 | Month 10 | 442.0 cells/mm^3 |
| HIV+/Aluminium Hydroxide Group | Number of CD4+ Cells Per Cubic Millimeter in All HIV+ Subjects at Month 10 and Month 12 | Month 12 | 453.0 cells/mm^3 |
Primary
Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7
The number of CD4+ cells per cubic millimeter (mm\^3) in all HIV+ subjects at pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 is reported.
Time frame: At pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all HIV+ vaccinated subjects for whom data were available at the considered time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 1 | 464.0 cells/mm^3 |
| HIV+/Cervarix Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 4 | 469.0 cells/mm^3 |
| HIV+/Cervarix Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Pre-vaccination (Day 0) | 451.0 cells/mm^3 |
| HIV+/Cervarix Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 6 | 452.0 cells/mm^3 |
| HIV+/Cervarix Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 2 | 436.0 cells/mm^3 |
| HIV+/Cervarix Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 7 | 419.0 cells/mm^3 |
| HIV+/Aluminium Hydroxide Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 2 | 438.0 cells/mm^3 |
| HIV+/Aluminium Hydroxide Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Pre-vaccination (Day 0) | 458.0 cells/mm^3 |
| HIV+/Aluminium Hydroxide Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 1 | 426.0 cells/mm^3 |
| HIV+/Aluminium Hydroxide Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 7 | 464.0 cells/mm^3 |
| HIV+/Aluminium Hydroxide Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 4 | 423.0 cells/mm^3 |
| HIV+/Aluminium Hydroxide Group | Number of Cluster of Differention 4 (CD4+) Cells Per Cubic Millimeter in All HIV+ Subjects at Pre-vaccination (Day 0) and Months 1, 2, 4, 6 and 7 | Month 6 | 426.0 cells/mm^3 |
Primary
Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Month 12
Seroconversion is defined as the appearance of anti-HPV-16 and/or anti-HPV-18 antibodies (anti-HPV-16 titers ≥ 8 ELISA units per milliliter (EL.U/mL) and anti-HPV-18 titers ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject whose antibody titers are below the cut-off value. Due to the high proportion of initially seropositive subjects in the study population, seroconversion rates were considered for all subjects in the ATP cohort for immunogenicity regardless of baseline serostatus.
Time frame: At Month 12
Population: The analysis was performed on ATP cohort for immunogenicity (Month 12), which included all evaluable subjects up to Month 12 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-16, At Month 12 | 41 Participants |
| HIV+/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-18, At Month 12 | 42 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-16, At Month 12 | 28 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-18, At Month 12 | 24 Participants |
| HIV-/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-16, At Month 12 | 22 Participants |
| HIV-/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Month 12 | anti-HPV-18, At Month 12 | 22 Participants |
Primary
Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7
Seroconversion is defined as the appearance of anti-HPV-16 and/or anti-HPV-18 antibodies (anti-HPV-16 titers ≥ 8 EL.U/mL and anti-HPV-18 titers ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject whose antibody titers are below the cut-off value. Due to the high proportion of initially seropositive subjects in the study population, seroconversion rates were considered for all subjects in the According-to-Protocol (ATP) cohort for immunogenicity regardless of baseline serostatus.
Time frame: At pre-vaccination (Day 0) and Months 2 and 7
Population: The analysis was performed on the ATP cohort for immunogenicity (Month 7), which included all evaluable subjects up to Month 7 for whom immunogenicity data were available at the considered time points. This included subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component post-vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 7 | 43 Participants |
| HIV+/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 7 | 42 Participants |
| HIV+/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 2 | 42 Participants |
| HIV+/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Day 0 | 35 Participants |
| HIV+/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Day 0 | 27 Participants |
| HIV+/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 2 | 41 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Day 0 | 24 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 2 | 26 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 2 | 31 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 7 | 25 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Day 0 | 30 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 7 | 31 Participants |
| HIV-/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 7 | 24 Participants |
| HIV-/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Day 0 | 14 Participants |
| HIV-/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 2 | 24 Participants |
| HIV-/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-16, At Month 7 | 24 Participants |
| HIV-/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Day 0 | 11 Participants |
| HIV-/Cervarix Group | Number of Seroconverted Subjects for HPV-16 and HPV-18 Antibodies at Pre-vaccination (Day 0) and Months 2 and 7 | anti-HPV-18, At Month 2 | 24 Participants |
Primary
Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12
CD4+ cell count categories, at baseline, assessed were: (i) below (\<) 200 CD4+ cells per cubic millimeter (mm\^3), (ii) between 200 and 500 CD4+ cells/mm\^3 and (iii) above (\>) 500 CD4+ cells/mm\^3. WHO classification of HIV-associated clinical disease: 1 = Asymptomatic HIV-associated symptoms = WHO clinical stage 1; 2 = Mild HIV-associated symptoms = WHO clinical stage 2; 3 = Advanced HIV-associated symptoms = WHO clinical stage 3; 4 = Severe HIV-associated symptoms = WHO clinical stage 4.
Time frame: At Month 10 and Month 12
Population: The analysis was performed on the Total Vaccinated cohort, which included all HIV+ vaccinated subjects for whom data were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 2] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 1] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 2] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 2] Month 12 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 3] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 3] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 3] Month 10 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 4] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 3] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 1] Month 12 | 24 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 4] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 2] Month 12 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 1] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 3] Month 12 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 4] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 4] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 2] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 1] Month 12 | 20 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 1] Month 10 | 21 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 2] Month 12 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 3] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 1] Month 10 | 26 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 4] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 4] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 3] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 1] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 2] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 3] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 4] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 1] Month 10 | 25 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 2] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 3] Month 10 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 4] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 1] Month 10 | 18 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 2] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 3] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 4] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 1] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 2] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | <200 CD4+cells/mm^3 [stage 4] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 1] Month 12 | 23 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 2] Month 12 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 3] Month 12 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | 200-500 CD4+cells/mm^3 [stage 4] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 1] Month 12 | 17 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 2] Month 12 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 3] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Month 10 and Month 12 | >500 CD4+cells/mm^3 [stage 4] Month 12 | 0 Participants |
Primary
Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7
CD4+ cell count categories, at baseline, assessed were (i) below (\<) 200 CD4+ cells per cubic millimeter (mm\^3), (ii) between 200 and 500 CD4+ cells/mm\^3 and (iii) above 500 CD4+ cells/mm\^3. WHO classification of HIV-associated clinical disease: 1 = Asymptomatic HIV-associated symptoms = WHO clinical stage 1; 2 = Mild HIV-associated symptoms = WHO clinical stage 2; 3 = Advanced HIV-associated symptoms = WHO clinical stage 3; 4 = Severe HIV-associated symptoms = WHO clinical stage 4.
Time frame: At Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all HIV+ vaccinated subjects for whom data were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 6 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 6 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 4 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 6 | 23 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 1 | 31 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 4 | 28 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 1 | 23 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 6 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 2 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 2 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 2 | 30 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 2 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 7 | 28 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 4 | 23 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 2 | 22 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Mth 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 4 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 4 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 6 | 28 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 7 | 21 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 6 | 19 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 4 | 27 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 4 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 4 | 20 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 6 | 28 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 6 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 7 | 28 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 7 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 7 | 19 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 1 | 33 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 1 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 1 | 20 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 4] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 2] Month 2 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 3] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 4] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 1] Month 2 | 19 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 2] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 3] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | >500 CD4+cells/mm^3 [stage 4] Mth 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 1] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 2] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | <200 CD4+cells/mm^3 [stage 3] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects in Each World Health Organisation (WHO) HIV Clinical Stage by CD4+ Cell Count Category at Baseline in All HIV+ Subjects at Months 1, 2, 4, 6 and 7 | 200-500 CD4+cells/mm^3 [stage 1] Month 2 | 33 Participants |
Primary
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms
Solicited local symptoms assessed were pain and swelling. Any = occurrence of any solicited local regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 swelling = swelling spreading beyond 50 millimeters (mm) of injection site. Solicited local symptoms were assessed as related to the study vaccination.
Time frame: Within 7 days after each dose and across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who had their symptom sheet filled in and for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 29 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 27 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 12 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 52 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 19 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 18 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 12 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 27 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 28 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 8 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 19 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 19 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 12 Participants |
Primary
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within 30 days after any vaccination
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Grade 3 unsolicited AE(s) | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Any unsolicited AE(s) | 53 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Related unsolicited AE(s) | 16 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Grade 3 unsolicited AE(s) | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Any unsolicited AE(s) | 46 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Related unsolicited AE(s) | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Any unsolicited AE(s) | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Related unsolicited AE(s) | 7 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Symptoms | Grade 3 unsolicited AE(s) | 0 Participants |
Primary
Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms
Solicited general symptoms assessed were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal, headache, myalgia, rash and urticaria. Any = occurrence of any solicited general symptom regardless of their intensity grade or relationship. Grade 3 Symptom = symptom that prevented normal activity. Grade 3 Urticaria = Urticaria distributed on at least 4 body areas. Related = symptom assessed by the investigator as causally related to the vaccination.
Time frame: Within 7 days after each dose and across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who had their symptom sheet filled in and for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Across doses | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 10 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Across doses | 15 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Across doses | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 2 | 11 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 1 | 13 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Across doses | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 2 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Across doses | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Across doses | 23 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 1 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Across doses | 18 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Across doses | 10 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Across doses | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Across doses | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Across doses | 15 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 12 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Across doses | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Across doses | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 3 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Across doses | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Across doses | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 3 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 3 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 3 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Across doses | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Across doses | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Across doses | 16 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Across doses | 12 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Across doses | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Across doses | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Across doses | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Across doses | 26 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Across doses | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Across doses | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Across doses | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Across doses | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Across doses | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Across doses | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 13 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 2 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 1 | 16 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 2 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 1 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 3 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 1 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 3 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 3 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 1 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 3 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 3 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 1 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 1 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 7 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 5 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 1 | 9 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 1 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 1 | 11 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 2 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 2 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Dose 3 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Dose 3 | 6 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Dose 3 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Dose 3 | 6 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Urticaria, Dose 3 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Arthralgia, Across doses | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Arthralgia, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Arthralgia, Across doses | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fatigue, Across doses | 8 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fatigue, Across doses | 7 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Fever, Across doses | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Fever, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Fever, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Gastrointestinal, Across doses | 13 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Gastrointestinal, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Gastrointestinal, Across doses | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Headache, Across doses | 16 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Headache, Across doses | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Myalgia, Across doses | 7 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Myalgia, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Myalgia, Across doses | 7 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Rash, Across doses | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Rash, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Related Rash, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Any Urticaria, Across doses | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms | Grade 3 Urticaria, Across doses | 0 Participants |
Primary
Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7
Haematological laboratory parameters assessed were haemoglobin (Hgb) and haematocrit (Hct). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated).
Time frame: At Day 7 and Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom assay results were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 4 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 1 | 12 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 1 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 6 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 6 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 4 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 7 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 1 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 7 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 7 | 34 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Day 7 | 11 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Day 7 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 6 | 42 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 6 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 6 | 36 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 1 | 42 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 6 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 1 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 4 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 2 | 37 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 4 | 38 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 2 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 7 | 43 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 7 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 7 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 7 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 7 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 2 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 6 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 6 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 1 | 10 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Day 7 | 13 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 4 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 4 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 2 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 2 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 2 | 12 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 2 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 4 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 4 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Day 7 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Day 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 1 | 43 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 1 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 2 | 43 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 2 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 4 | 43 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 4 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 6 | 39 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 6 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 7 | 38 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 7 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 1 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 1 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 2 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 2 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 4 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 4 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 6 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 6 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 7 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 7 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Day 7 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Day 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 1 | 37 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 1 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 2 | 36 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 2 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 4 | 36 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 4 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 6 | 33 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 6 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 7 | 30 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 7 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 1 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 1 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 2 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 2 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 4 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 4 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 6 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 6 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 7 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 1 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 4 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 2 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 2 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 2 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 1 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 6 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 7 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 1 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 7 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 1 | 23 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 2 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 4 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Day 7 | 13 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 1 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 1 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 6 | 23 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 6 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Day 7 | 13 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Normal] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Normal] Month 7 | 20 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Below] Month 7 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Above] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 7 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Normal] Month 4 | 23 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Below] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Normal] Month 6 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hct [pre-vacc Low; post-vacc Normal] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Haemoglobin and Haematocrit Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | Hgb [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
Primary
Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7
Haematological laboratory parameters assessed were lymphocytes (LYM) and monocytes (MON). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated).
Time frame: At Day 7 and at Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom assay results were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 2 | 52 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Day 7 | 12 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 2 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 4 | 51 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 1 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 4 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 6 | 53 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 6 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 7 | 50 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 7 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Day 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 2 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 2 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 4 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 4 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 4 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 4 | 49 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 6 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 4 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 6 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 1 | 52 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 4 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 6 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 6 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 7 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 6 | 48 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 6 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 4 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 7 | 48 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 6 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Day 7 | 13 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Day 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 2 | 50 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 1 | 56 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 2 | 55 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 4 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 1 | 55 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 4 | 52 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 7 | 49 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 2 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 6 | 52 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 7 | 50 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 7 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 2 | 54 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 6 | 52 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Day 7 | 14 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 1 | 54 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Day 7 | 14 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 4 | 50 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Day 7 | 14 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 1 | 27 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 2 | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 4 | 23 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 6 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 6 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Normal] Month 7 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Above] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Normal] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Normal] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | LYM [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Day 7 | 15 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 1 | 28 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 2 | 28 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 4 | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 6 | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Normal] Month 7 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Below] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Normal] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Lymphocytes and Monocytes Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | MON [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
Primary
Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12
Haematological laboratory parameters assessed were neutrophils (NEU), platelets (PLA), red blood cells (RBC) and white blood cells (WBC). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated).
Time frame: At Month 10 and Month 12
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom assay results were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Above] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Normal] Month 12 | 40 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Normal] Month 10 | 48 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Below] Month 10 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Below] Month 10 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Below] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Normal] Month 10 | 40 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Missing] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Normal] Month 10 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Normal] Month 12 | 50 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Normal] Month 12 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Normal] Month 12 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Normal] Month 10 | 32 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Above] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Normal] Month 12 | 34 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Normal] Month 10 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Below] Month 10 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Normal] Month 12 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Normal] Month 10 | 35 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Below] Month 12 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Normal] Month 12 | 29 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Below] Month 12 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Below] Month 12 | 13 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Below] Month 10 | 11 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Below] Month 12 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Normal] Month 10 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Below] Month 10 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Below] Month 10 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Below] Month 12 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Below] Month 12 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Below] Month 12 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Normal] Month 12 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Normal] Month 12 | 49 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Normal] Month 12 | 40 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Below] Month 10 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Normal] Month 12 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Below] Month 12 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Normal] Month 12 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Normal] Month 10 | 30 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Below] Month 10 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Above] Month 10 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Normal] Month 12 | 32 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Below] Month 12 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Normal] Month 10 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Below] Month 10 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Below] Month 12 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Normal] Month 10 | 47 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Below] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Missing] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Normal] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Normal] Month 10 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Normal] Month 12 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Normal] Month 10 | 34 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Below] Month 10 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Below] Month 12 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Below] Month 12 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Normal] Month 10 | 36 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Below] Month 10 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Above] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Normal] Month 12 | 35 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Normal] Month 10 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Below] Month 10 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Below] Month 12 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Normal] Month 10 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Normal] Month 12 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Normal] Month 12 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Below] Month 12 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Below] Month 12 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Normal] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Below] Month 10 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Low; post-vacc Normal] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Below] Month 12 | 5 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Below] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Normal] Month 12 | 17 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Below] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Normal] Month 12 | 17 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Below] Month 12 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Below] Month 10 | 5 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Normal] Month 10 | 19 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | NEU [pre-vacc Normal; post-vacc Normal] Month 10 | 16 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Normal] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Low; post-vacc Normal] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Below] Month 10 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Normal] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Normal] Month 12 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | PLA [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | WBC [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells at Month 10 and Month 12 | RBC [pre-vacc Normal; post-vacc Normal] Month 10 | 23 Participants |
Primary
Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7
Haematological laboratory parameters assessed were red blood cells (RBC) and platelets (PLA). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated).
Time frame: At Day 7 and at Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom assay results were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Day 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 4 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 4 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 7 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 2 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 6 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 7 | 43 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 1 | 56 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 4 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 4 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 6 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 7 | 51 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 6 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 6 | 40 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 2 | 51 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 1 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 2 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 4 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 1 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 4 | 43 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 4 | 52 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 2 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 2 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 4 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 7 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 2 | 44 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 6 | 53 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 1 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 4 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 1 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 2 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Day 7 | 14 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Day 7 | 13 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 6 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 6 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 4 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 4 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 6 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 6 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 7 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 7 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Day 7 | 14 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 1 | 54 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 2 | 54 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 4 | 51 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 6 | 52 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 1 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 2 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 7 | 50 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Day 7 | 12 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Day 7 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 1 | 44 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 1 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 2 | 45 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 2 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 4 | 40 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 4 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 6 | 40 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 6 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 7 | 37 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 7 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 1 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 1 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 2 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Day 7 | 15 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Day 7 | 15 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 1 | 25 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 1 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 6 | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 2 | 28 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 4 | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 4 | 25 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 2 | 28 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 6 | 25 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 7 | 25 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Normal] Month 1 | 29 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Normal] Month 7 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Below] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Normal] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Normal] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | RBC [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in Red Blood Cells and Platelets Parameters at Day 7 and at Months 1, 2, 4, 6 and 7 | PLA [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
Primary
Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7
Haematological laboratory parameters assessed were white blood cells (WBC) and neutrophils (NEU). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated).
Time frame: At Day 7 and Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom assay results were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 2 | 10 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 2 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 4 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 4 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 4 | 36 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 4 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 4 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 2 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 4 | 37 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 2 | 38 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 6 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 6 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 4 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 1 | 11 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 1 | 39 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 1 | 36 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 7 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 2 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 7 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Day 7 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Day 7 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 2 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Day 7 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 6 | 35 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 1 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 6 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Day 7 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 1 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 6 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 1 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 7 | 34 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 7 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Day 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 7 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 6 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 2 | 38 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 7 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 7 | 35 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 1 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 2 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 1 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 7 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 6 | 12 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 4 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 6 | 33 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 2 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Day 7 | 12 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Day 7 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 1 | 43 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 1 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 2 | 41 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 2 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 4 | 41 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 4 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 6 | 38 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 6 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 7 | 38 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 7 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 1 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 1 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 2 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 4 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 4 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 6 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 6 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 7 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Day 7 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Day 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 1 | 36 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 1 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 2 | 35 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 2 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 4 | 30 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 4 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 6 | 33 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 6 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 7 | 32 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 7 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 1 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 1 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 2 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 2 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 4 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 4 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 6 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 6 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 7 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 7 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 6 | 19 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 4 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 6 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 1 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 2 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 7 | 18 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 7 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 7 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 7 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Day 7 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 1 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 7 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 6 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 6 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 1 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 6 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 1 | 23 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Day 7 | 12 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Day 7 | 12 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 4 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 1 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Below] Month 2 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 1 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 6 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Normal] Month 4 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 2 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 2 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Normal] Month 4 | 19 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Below] Month 4 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Below] Month 2 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Low; post-vacc Normal] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | WBC [pre-vacc Normal; post-vacc Below] Month 2 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Clinically Relevant Abnormalities in White Blood Cells and Neutrophils Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | NEU [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
Primary
Number of Subjects Reporting SAEs From Day 0 up to Month 12
SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 0 up to Month 12
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting SAEs From Day 0 up to Month 12 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting SAEs From Day 0 up to Month 12 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting SAEs From Day 0 up to Month 12 | 1 Participants |
Primary
Number of Subjects Reporting Serious Adverse Events (SAEs) From Day 0 up to Month 7
SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 0 up to Month 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV+/Cervarix Group | Number of Subjects Reporting Serious Adverse Events (SAEs) From Day 0 up to Month 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects Reporting Serious Adverse Events (SAEs) From Day 0 up to Month 7 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects Reporting Serious Adverse Events (SAEs) From Day 0 up to Month 7 | 1 Participants |
Primary
Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12
Haematological and biochemical laboratory parameters assessed were alanine aminotransferase (ALAT), basophils (BAS), creatinine (CREA), eosinophils (EOS), haematocrit (Hct), haemoglobin (Hgb), lymphocytes (LYM) and monocytes (MON). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated).
Time frame: At Month 10 and Month 12
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom assay results were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Normal] Month 10 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Normal] Month 12 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Normal] Month 12 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Above] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Above] Month 10 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Normal] Month 12 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Normal] Month 12 | 43 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Above] Month 12 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Above] Month 12 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Normal] Month 10 | 55 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Below] Month 10 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Normal] Month 12 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Normal] Month 12 | 54 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Normal] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Below] Month 12 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Normal] Month 10 | 20 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Below] Month 12 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Normal] Month 12 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Below] Month 12 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Normal] Month 12 | 18 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Below] Month 12 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Below] Month 12 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Normal] Month 10 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Normal] Month 10 | 11 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Below] Month 12 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Below] Month 10 | 20 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Normal] Month 12 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Normal] Month 12 | 50 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Below] Month 10 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Normal] Month 10 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Normal] Month 12 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Below] Month 12 | 26 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Normal] Month 12 | 45 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Normal] Month 10 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal ; post-vacc Above] Month 10 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Below] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Below] Month 10 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Below] Month 10 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Below] Month 10 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Normal] Month 10 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Normal] Month 10 | 50 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Normal] Month 12 | 38 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Normal] Month 10 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Normal] Month 12 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Normal] Month 10 | 44 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Normal] Month 10 | 44 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Below] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Below] Month 12 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Above] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Below] Month 10 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Normal] Month 10 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Normal] Month 12 | 32 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Above] Month 12 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Normal] Month 12 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Below] Month 12 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Normal] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Below] Month 12 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Below] Month 10 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Normal] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Below] Month 10 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Normal] Month 10 | 35 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Below] Month 12 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Normal] Month 10 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Above] Month 12 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Normal] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Normal] Month 12 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Normal] Month 12 | 39 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Above] Month 10 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Normal] Month 12 | 52 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Below] Month 10 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Below] Month 10 | 13 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal ; post-vacc Above] Month 10 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Normal] Month 12 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Normal] Month 10 | 31 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Below] Month 10 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Normal] Month 12 | 32 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Below] Month 12 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Normal] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Below] Month 10 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Normal] Month 10 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Below] Month 10 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Below] Month 12 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Normal] Month 10 | 48 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Below] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Normal] Month 12 | 48 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Normal] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Normal] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Normal] Month 10 | 40 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Above] Month 10 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Above] Month 12 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Normal] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Normal] Month 10 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Normal] Month 12 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Above] Month 12 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Normal] Month 10 | 50 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Normal] Month 10 | 22 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Normal] Month 12 | 24 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Below] Month 12 | 10 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Normal] Month 10 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Below] Month 12 | 14 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Normal] Month 12 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Below] Month 12 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Above] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Normal] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Normal] Month 10 | 46 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Normal] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Normal] Month 12 | 49 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Above] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Normal] Month 10 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Below] Month 12 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Normal] Month 10 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Below] Month 10 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Normal] Month 10 | 48 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Normal] Month 12 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Below] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Normal] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Below] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Normal] Month 12 | 45 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Below] Month 12 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Above] Month 12 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Normal] Month 10 | 38 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal ; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Normal] Month 12 | 42 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Below] Month 12 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Normal] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Normal] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Normal] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Below] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Normal] Month 10 | 20 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Below] Month 10 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal ; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Above] Month 12 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Normal] Month 12 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Normal] Month 12 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Normal] Month 12 | 20 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Normal] Month 10 | 20 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Normal] Month 10 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Normal] Month 12 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Normal] Month 12 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal ; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Normal] Month 10 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Normal] Month 12 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Below] Month 12 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Below] Month 12 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Below] Month 10 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Normal] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Normal] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Below] Month 12 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Above] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Below] Month 10 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Normal] Month 10 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low ; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Normal] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Below] Month 10 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Normal] Month 12 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Normal] Month 12 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Low; post-vacc Normal] Month 10 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Above] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Normal] Month 12 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Below] Month 12 | 6 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Normal] Month 12 | 13 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Above] Month 10 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Normal] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Above] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | CREA [pre-vacc Normal; post-vacc Normal] Month 10 | 15 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc Low; post-vacc Normal] Month 12 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Normal] Month 10 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Normal] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Normal] Month 10 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Normal] Month 12 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | LYM [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hgb [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal ; post-vacc Above] Month 10 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Low; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | BAS [pre-vacc Normal; post-vacc Normal] Month 10 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Normal] Month 12 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Above] Month 12 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Above] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Below] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | MON [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc Normal; post-vacc Missing] Month 12 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | Hct [pre-vacc Low; post-vacc Missing] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Normal] Month 10 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | ALAT [pre-vacc High; post-vacc Normal] Month 12 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters at Month 10 and Month 12 | EOS [pre-vacc High; post-vacc Below] Month 10 | 0 Participants |
Primary
Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7
Biochemical laboratory parameter assessed was alanine aminotransferase (ALAT). By pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated).
Time frame: At Day 7 and Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom assay results were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 1 | 48 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 4 | 44 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 1 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 4 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 7 | 40 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 4 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 6 | 46 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 2 | 47 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 6 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 1 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 6 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 1 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Day 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 2 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Day 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 6 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 7 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 4 | 9 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 6 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Day 7 | 10 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 7 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 6 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 2 | 40 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 6 | 41 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 6 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 7 | 40 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 7 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 2 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Day 7 | 12 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 7 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 1 | 45 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 2 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 4 | 42 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 4 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Day 7 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 1 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 1 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 2 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 4 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 4 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 6 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Day 7 | 12 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 7 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 7 | 22 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 6 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 2 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Day 7 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 6 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 4 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 1 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 4 | 23 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 6 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 2 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Above] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Normal] Month 1 | 25 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc High; post-vacc Normal] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Alanine Aminotransferase Parameter at Day 7 and Months 1, 2, 4, 6 and 7 | ALAT [pre-vacc Low; post-vacc Below] Month 4 | 0 Participants |
Primary
Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7
Haematological and biochemical laboratory parameters assessed were eosinophils (EOS), basophils (BAS) and creatinine (CREA). For each parameter and by pre-vaccination status, it was assessed whether the post-vaccination values of the parameter were above, below or in the normal range (missing values are also indicated).
Time frame: At Day 7 and at Months 1, 2, 4, 6 and 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom assay results were available at the considered time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 2 | 26 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 1 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 6 | 50 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 7 | 50 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 2 | 8 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 6 | 21 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Day 7 | 13 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 2 | 23 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Day 7 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 1 | 53 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 6 | 20 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 1 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 1 | 24 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 2 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 4 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 4 | 24 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 2 | 51 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 6 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 6 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 4 | 25 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 4 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 4 | 48 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 4 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 6 | 10 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 2 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 1 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Day 7 | 15 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 4 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 7 | 22 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 1 | 60 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 7 | 7 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 7 | 3 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 6 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 7 | 24 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Day 7 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 2 | 58 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Day 7 | 6 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 7 | 4 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 4 | 57 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 4 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 6 | 57 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Day 7 | 1 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 1 | 5 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 6 | 2 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 1 | 27 Participants |
| HIV+/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 7 | 56 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 1 | 13 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Day 7 | 4 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 6 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Day 7 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 4 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 1 | 29 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 1 | 8 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 2 | 30 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 4 | 9 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 6 | 51 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 6 | 22 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 7 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 6 | 12 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Day 7 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Day 7 | 15 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 2 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 7 | 49 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 2 | 15 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 4 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 4 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 4 | 12 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 6 | 13 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 7 | 5 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 7 | 13 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 4 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 1 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 2 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 1 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Day 7 | 13 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Day 7 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 1 | 52 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 7 | 53 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 1 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 2 | 51 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 4 | 26 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 2 | 3 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 6 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 4 | 49 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 2 | 2 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 7 | 24 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 1 | 57 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 6 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 7 | 11 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 2 | 57 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Day 7 | 6 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 2 | 1 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 4 | 54 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 6 | 54 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 1 | 7 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 6 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Day 7 | 15 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 2 | 6 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 4 | 17 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 4 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 7 | 15 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Day 7 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 6 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 6 | 25 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 7 | 24 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Day 7 | 15 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 1 | 28 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 2 | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Above] Month 2 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Normal] Month 4 | 25 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc Normal; post-vacc Below] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 1 | 29 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 2 | 28 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 4 | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 6 | 26 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Normal] Month 7 | 25 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Below] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | BAS [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Day 7 | 11 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Day 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 1 | 17 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 1 | 5 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 2 | 15 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Normal] Month 6 | 17 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 6 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Below] Month 7 | 5 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Normal; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Day 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 1 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 1 | 6 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 1 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 2 | 2 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 2 | 5 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 4 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 4 | 5 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 6 | 3 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Normal] Month 7 | 1 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Below] Month 7 | 4 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Above] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | CREA [pre-vacc Low; post-vacc Missing] Month 7 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Missing] Month 2 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Above] Month 4 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Normal] Month 6 | 0 Participants |
| HIV-/Cervarix Group | Number of Subjects With Clinically Relevant Abnormalities in Eosinophils, Basophils and Creatinine Parameters at Day 7 and Months 1, 2, 4, 6 and 7 | EOS [pre-vacc High; post-vacc Below] Month 6 | 0 Participants |
Primary
Number of Subjects With Medically Significant Conditions (MSCs) From Day 0 up to Month 7
Medically significant conditions (MSCs) were collected regardless of causal relationship to vaccination and intensity. Medically significant conditions were defined as adverse events (AEs) prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or serious adverse events (SAEs) that were not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.
Time frame: From Day 0 up to Month 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV+/Cervarix Group | Number of Subjects With Medically Significant Conditions (MSCs) From Day 0 up to Month 7 | 18 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Medically Significant Conditions (MSCs) From Day 0 up to Month 7 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects With Medically Significant Conditions (MSCs) From Day 0 up to Month 7 | 5 Participants |
Primary
Number of Subjects With MSCs From Day 0 up to Month 12
MSCs were collected regardless of causal relationship to vaccination and intensity. Medically significant conditions were defined as adverse events (AEs) prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or serious adverse events (SAEs) that were not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.
Time frame: From Day 0 up to Month 12
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV+/Cervarix Group | Number of Subjects With MSCs From Day 0 up to Month 12 | 19 Participants |
| HIV+/Aluminium Hydroxide Group | Number of Subjects With MSCs From Day 0 up to Month 12 | 21 Participants |
| HIV-/Cervarix Group | Number of Subjects With MSCs From Day 0 up to Month 12 | 5 Participants |
Primary
Number of Subjects With Pregnancies and Outcomes of Reported Pregnancies From Day 0 up to Month 12
The subjects with confirmed pregnancies were followed up to determine the outcomes of the reported pregnancies. The outcome of the reported pregnancy was a live infant with no apparent congenital anomaly.
Time frame: From Day 0 up to Month 12
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who reported pregnancies and outcomes of reported pregnancies.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Pregnancies and Outcomes of Reported Pregnancies From Day 0 up to Month 12 | 1 Participants |
Primary
Number of Subjects With Pregnancies and Outcomes of Reported Pregnancies From Day 0 up to Month 7
The subjects with confirmed pregnancies were followed up to determine the outcomes of the reported pregnancies. The outcome of the reported pregnancy was a live infant with no apparent congenital anomaly.
Time frame: From Day 0 up to Month 7
Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects who reported pregnancies and outcomes of reported pregnancies.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HIV+/Aluminium Hydroxide Group | Number of Subjects With Pregnancies and Outcomes of Reported Pregnancies From Day 0 up to Month 7 | 1 Participants |